BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) yesterday and set a price target of $1,010.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Evan Seigerman has given his Buy rating due to a combination of factors including Eli Lilly & Co’s robust commercial execution and promising pipeline developments. The company is effectively managing its supply dynamics, as evidenced by its plans for a significant manufacturing capacity expansion in the first half of 2025, which positions it well to capitalize on competitive opportunities, especially in international markets.
Furthermore, the focus on Orforglipron, a key pipeline candidate, with multiple anticipated readouts in 2025, suggests potential for strong future performance. Seigerman also highlights the company’s strategic advancements in diabetes and oncology, which are expected to drive sustainable growth and contribute positively to the company’s financial outlook.
According to TipRanks, Seigerman is a 4-star analyst with an average return of 7.2% and a 48.97% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Amgen, Merck & Company, and Novo Nordisk.
In another report released today, Bank of America Securities also reiterated a Buy rating on the stock with a $1,000.00 price target.